S-1 as First-line Chemo for HER2- Metastatic Breast Cancer

S-1 is just as effective in terms of overall survival as a taxane as first-line treatment for patients with metastatic breast cancer.
S-1 is just as effective in terms of overall survival as a taxane as first-line treatment for patients with metastatic breast cancer.

S-1, an oral fluoropyrimidine, is just as effective in terms of overall survival as a taxane as first-line treatment for patients with metastatic breast cancer, a new study published online ahead of print in the journal The Lancet Oncology has shown.1

Although oral fluoropyrimidine like capecitabine are used for the first-line treatment of metastatic breast cancer in order to avoid severe adverse events, clear evidence for this approach is lacking. Therefore, researchers sought to assess whether S-1 is noninferior to taxanes in this setting.

For the open-label, phase 3 trial, researchers in Japan enrolled 618 patients with human epidermal growth factor receptor 2 (HER2)-negative breast cancer who were resistant to endocrine therapy and had received no chemotherapy for advanced disease.

Patients were randomly assigned 1:1 to receive a taxane (docetaxel or paclitaxel every 3 to 4 weeks or paclitaxel weekly) or S-1 orally twice daily for 28 consecutive days, followed by a 2-week break.

Results showed that after a median follow-up of 34.6 months, median overall survival was 35.0 months (95% CI: 31.1-39.0) with S-1 compared with 37.2 months (95% CI: 33.0-40.1) with a taxane (HR, 1.05; 95% CI: 0.86-1.27; Pnon-inferiority=.015).

In regard to safety, the most common grade 3 or higher adverse events in the S-1 group were neutropenia, fatigue, and edema.

“S-1 should be considered a new option for first-line chemotherapy for patients with HER2-negative metastatic breast cancer,” the authors conclude.

REFERENCE

1. Takashima T, Mukai H, Hara F, et al. Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial [published online ahead of print November 23, 2015]. Lancet Oncol. doi:10.1016/S1470-2045(15)00411-8.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs